Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen
Recruiting
Biohaven Pharmaceuticals, Inc.
Phase 2/Phase 3
2020-04-25
The purpose of this study is to determine if a CGRP receptor antagonist may potentially blunt
the severe inflammatory response at the alveolar level, delaying or reversing the path
towards oxygen desaturation, ARDS, requirement for supplemental oxygenation, artificial
ventilation or death in patients with COVID-19 on supplemental oxygen.
* BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant). The
World Health Organization (WHO) International Nonproprietary Names (INN) Expert Committee
revised the name to "zavegepant" which was accepted by the United States Adopted Names (USAN
) Council for use in the U.S. and is pending formal adoption by the INN for international
use.
Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine
Active, not recruiting
Biohaven Pharmaceuticals, Inc.
Phase 2/Phase 3
2020-06-29
The purpose of this study is to evaluate the long-term safety of BHV-3500/vazegepant
intranasal in the acute treatment of migraine.
* BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant). The
World Health Organization (WHO) International Nonproprietary Names (INN) Expert Committee
revised the name to "zavegepant" which was accepted by the United States Adopted Names (USAN
) Council for use in the U.S. and is pending formal adoption by the INN for international
use.
A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
Recruiting
Biohaven Pharmaceutical Holding Company Ltd.
Phase 2/Phase 3
2021-03-26
The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo
as a preventive treatment for migraine, as measured by the reduction in the number of
migraine days per month.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
